|Unit Price:||USD 1.0000 / Kilogram |
|Min. Order:||1 Kilogram|
|Delivery Time:||15 Days|
Model No.: 1197958-12-5
Packaging: AS REQUIRED
Place of Origin: CHINA
Supply Ability: TRUE MANUFACTURER
AP26113 CAS number 1197958-12-5 is treated for metastatic ALK-positive non-small cell lung cancer resistant to methotrexate. The US FDA has granted eligibility for its breakthrough treatment. In the I / II phase trial, AP26113 had persistent anti-tumor activity in ALK-positive non-small cell lung cancer patients, including brain metastases. The I / II trial data for AP26113 was updated at this year's ESMO meeting (abstract No. 1292P). A total of 137 patients were enrolled in the United States and Europe. The results show that AP26113 is effective in patients with ALK-positive non-small cell lung cancer, including those who are insensitive to tyrosine kinase inhibitors (TKI) and those resistant to methotrexate.
72% of the objective is effective, the median effective time for 49 weeks, the median progression-free survival of 56 weeks. Another story of the "magical pill" was replicated, and it was surprising and impressive to patients who were resistant to Crizotinib . FDA is not rigidly adhere to the policy, quickly give AP26113 as breakthrough drug, reflects its policy of flexibility , science and humanity.
Thera. Category: Anti-cancer
Synonyms:5-Chloro-N4-[2-(dimethylphosphinyl)phenyl]-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-2,4-pyrimidinediamine;Brigatinib;AP26113 (Brigatinib);Brigatinib, AP26113;
Molecular Weight: 575.039301
Packing: Export worthy packing
Material Safety Data Sheet: Available on request